Purpose of study
Osteonecrosis after treatment for ALL or lymphoblastic lymphoma is most common in older children and young people.
The aims of the study are:
- to find out how common it is for older children and young people treated for ALL or lymphoblastic lymphoma to develop osteonecrosis
- to find out when osteonecrosis develops during or after treatment
- to identify risk factors for the development of osteonecrosis
- to identify features that help predict whether osteonecrosis will progress (get worse) or get better.
Treatment for ALL or lymphoblastic lymphoma is usually very successful and the vast majority of children and young people with these diseases are cured.
Osteonecrosis is a bone problem that can develop in children and young people after treatment for ALL or lymphoblastic lymphoma. It happens when the blood supply to the bones is reduced. In some people, osteonecrosis causes painful symptoms and serious bone damage. These people need treatment to slow down the bone damage followed by surgery to replace or repair the bone.
The researchers collect information from your routine scans and tests.
You are also asked to have MRI scans and a physiotherapy assessment:
- within 2 weeks of diagnosis of ALL or lymphoblastic lymphoma
- at the end of the delayed intensification part of your treatment
- 1, 2, and 3 years after the start of the maintenance part of your treatment.
Your medical team will explain the different parts of treatment for ALL and lymphoblastic lymphoma.
Who can enter
Your consultant can give you advice on whether this study might be suitable for you.
Around 50 people are needed for this study.
You may be able to enter if:
- You have been diagnosed with ALL or lymphoblastic lymphoma.
- You have not received any treatment for ALL or lymphoblastic lymphoma.
- You are aged 10 to 24.
You will not be able to enter if:
- You can’t have MRI scans of your legs.
More information about this trial is available at clinicaltrials.gov.